Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02837042 · ClinicalTrials.gov registry record · Phase 2
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02837042 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 6 participants.
The verdict
NCT02837042, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits higher incidences in less developed countries. PSCC is a highly aggressive malignancy characterized by early spread. Pembrolizumab has recently been FDA-approved for the treatment of melanoma but will serve as the investigational agent for this penile cancer study.
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02837042
The ClinicalTrials.gov registry entry for NCT02837042 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02837042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02837042 about?
NCT02837042 is a clinical study titled "Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma". Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits higher incidences in less developed countries. PSCC is a highly aggressive malignancy characterized by early spread. Pembrolizumab has recently been FDA-approved for the treatment of melanoma but will serve as the investigational ...
What is the current status of trial NCT02837042?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2016-10. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02837042?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02837042?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.